A PHASE III RANDOMISED, DOUBLE-BLIND, FACTORIAL DESIGN STUDY TO ASSESS THE EFFECT OF FIXED DOSE COMBINATION LAROPROVSTAT/ROSUVASTATIN COMPARED WITH LAROPROVSTAT, ROSUVASTATIN, AND PLACEBO ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL

Registry ID

D7961C00002

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA CANADA INC

Last update

2026-07-17

Conditions

• HYPERCHOLESTEROLEMIA

Related clinical trials

• A PHASE 3, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK-0616 IN ADULTS WITH HYPERCHOLESTEROLEMIA
• "A MULTI-COUNTRY, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO DOCUMENT THE SAFETY, TOLERABLITY AND EFFECT OF ALIROCUMAB ON ATHEROGENIC LIPOPROTEINS IN HIGH CARDIO-VASCULAR RISK PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA NOT ADEQUATELY CONTROLLED WITH CONVENTIONAL LIPID-MODIFYING THERAPIES."
• A DOUBLE-BLIND, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AMG 145, COMPARED WITH EZETIMIBE, IN HYPERCHOLESTEROLEMIC SUBJECTS UNABLE TO TOLERATE AN EFFECTIVE DOSE OF A HMG-COA REDUCTASE INHIBITOR DUE TO MUSCLE RELATED SIDE EFFECTS
• "A MULTI-CENTER, RANDOMIZED STUDY IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPDEMIA TO ASSESS SUBJECTS' ABILITY TO ADMINISTER A FULL DOSE OF AMG 145 IN HOME-USE, USING EITHER A 3.5ML PERSONAL INJECTOR OR A PREFILLED AUTOINJECTOR/PEN."

View on source registry